1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

Technology appraisal guidance [TA756] Published: 16 December 2021

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 153 KB 16 December 2021  
  • Register of interests PDF 155 KB 16 December 2021  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 297 KB 17 November 2021  
  • Committee papers PDF 1.46 MB 17 November 2021  
  • Public committee slides PDF 717 KB 17 November 2021  
  • Final appraisal document Managed Access Agreement PDF 351 KB 17 November 2021  

Draft guidance

  • Draft guidance  
  • Appraisal consultation document (online commenting)  
  • Appraisal consultation document (PDF version) PDF 314 KB 07 July 2021  
  • Committee papers PDF 4.57 MB 07 July 2021  
  • Public committee slides PDF 1.11 MB 07 July 2021  

Invitation to participate

  • Final scope PDF 171 KB 07 May 2020  
  • Final stakeholder list PDF 192 KB 07 May 2020  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 167 KB 07 May 2020  
  • Equality impact assessment (Scoping) PDF 122 KB 07 May 2020  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope post referral PDF 206 KB 10 April 2019  
  • Draft matrix post referral PDF 190 KB 10 April 2019